[Life threatening neuroleptic malignant syndrome due to olanzapine].
The frequency of neuroleptic malignant syndrome (NMS) after clozapine or olanzapine is low and often of non-serious nature. A 49 year-old female patient developed NMS 12 days after olanzapine re-exposure. Olanzapine was stopped, the patient was transferred to an ICU and received a course of nine uni- and bilateral ECT treatments. This led to remission. 14 months earlier the patient had presented with a first severe NMS episode after haloperidol depot injection and 4 days after starting oral clozapine. Following the first NMS episode olanzapine (20 mg per day) was administered for 11 months without adverse effects.
Kopf
Andrea
A
Klinik und Poliklinik für Psychiatrie, Universitätsklinikum Leipzig, AöR.
Köster
Johannes
J
Schulz
Andreas
A
Krömker
Horst
H
Becker
Thomas
T
D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001569:Benzodiazepines; D003422:Critical Care; D004565:Electroconvulsive Therapy; D005260:Female; D006220:Haloperidol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008875:Middle Aged; D009459:Neuroleptic Malignant Syndrome / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy; D000077152:Olanzapine; D010890:Pirenzepine / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011618:Psychotic Disorders / Q000188:drug therapy*; D012008:Recurrence
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D010890:Pirenzepine; C033563:haloperidol decanoate; D006220:Haloperidol; D000077152:Olanzapine